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Available online 26 June 2014AbstractBackground: Angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic factors. Vascular endothelial growth factor
(VEGF) and endostatin respectively represents a frequent component of inducers and inhibitors in the process of angiogenesis. The ratio
of VEGF/endostatin may reflect the balance of angiogenic switch. This study aimed to determine whether an imbalance between VEGF/
endostatin exists in operable non-small cell lung cancer (NSCLC) patients and to assess the correlation, if any, between the imbalance and
the prognosis.
Methods: Preoperative serum levels of VEGF and endostatin were simultaneously determined by quantitiative enzyme-linked immunosor-
bent assay (ELISA) and the ratio of them was calculated among 98 NSCLC patients and 51 healthy controls. The relationship between these
factors and clinicopathological features, including prognosis, was examined.
Results: The ratio of VEGF/endostatin levels was significantly higher in operable NSCLC patients [median, 10.4; interquartile range (IQR),
5.9e19.8] than in normal controls [median, 5.1; IQR, 3.3e9.7] (P ¼ 0.002). While the ratio in patients who were still alive for more than 60
months was 8.3 (IQR, 4.3e17.9), the ratio in those who died was 12.9 (IQR, 8.0e22.1) ( p ¼ 0.017). In subgroup analysis of patients with
pathological stage N0, there was a statistically significant increase of the survival time in the group with a lower ratio than in the group with
a higher ratio ( p ¼ 0.032). Multivariate analysis confirmed that the VEGF/endostatin ratio was an independent prognostic factor
( p ¼ 0.018).
Conclusion: There was an imbalance between VEGF and endostatin in serum of operable NSCLC patients. The imbalance correlated with
the prognosis of operable NSCLC.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).
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Lung cancer is the most common cause of death from
cancer worldwide, estimated to be responsible for 19.4%
(1.59 million) of all cancer deaths in 2012.1 Despite diag-
nostic and therapeutic advances, the survival rate of lung
cancer patients is still low (10% after 5 years), and hashor. Tel.: þ86 10 89509309.
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).not changed over the period analyzed in the
EUROCARE-4 study.2 Non-small cell lung cancer
(NSCLC) is the most common histological type of lung
cancer, accounting for approximately 80% of lung cancers.3
In the 1970s, Folkman postulated that tumor growth and
metastasis are dependent on angiogenesis.4 And now the
importance of angiogenesis for the development of solid tu-
mors is well recognized. It is acknowledged that angiogen-
esis is regulated by both promoters and inhibitors. When
the stimulators accumulate in excess of inhibitors withiness article under the CC BY-NC-ND license (http://creativecommons.org/
1137Y. Hu et al. / EJSO 40 (2014) 1136e1142an angiogenic tumor, the balance between the inducers and
inhibitors is interrupted5 and the “angiogenic switch”
would be activated which progressively enhance the inten-
sity of angiogenesis.6 A variety pro-angiogenic factors have
been described including vascular endothelial growth factor
(VEGF).7 An increasing number of anti-angiogenic factors
such as endostatin and angiostatin also have been
identified.8
VEGF and endostatin are two factors which have been
reported in more detail about their roles in the angiogen-
esis. VEGF, which is also known as vascular permeability
factor (VPF), is the most powerful angiogenic factor known
to date with direct effects on endothelial cell proliferation,
migration and tubule formation under physiologic and path-
ologic conditions.9 It acts through binding to VEGF recep-
tor (VEGFR) generating a cascade of intracellular
signaling, leading to activation of transcription factors in
the nucleus that ultimately lead to new vessel formation.10
Endostatin, a strong endogenous inhibitor of angiogen-
esis which was discovered as a 20 kDa internal fragment
of the carboxy terminus of collagen XVIII, was reported
to be identified in a matrix protein in 1994,11 and was
proved to be an endogenous angiogenesis inhibitor and a
tumor suppressor in 2005.12 Endostatin which is the most
rigorously studied one of the endogenous angiogenesis in-
hibitors inhibits endothelial cell proliferation, migration/in-
vasion, tubule formation and increases apoptosis of
malignant cells.13
Our overall hypothesis was that there is an imbalance of
angiogenic factors in NSCLC patients since the balance of
the inhibitors and inducers controls the angiogenic switch.
Although there are many promoters and inhibitors involved
in NSCLC angiogenesis, VEGF and endostatin might pre-
liminarily represent the two categories respectively. This
is a retrospective cohort study designed to determine
whether an imbalance between VEGF and endostatin exists
in operable NSCLC patients and evaluate the possible prog-
nostic correlation of such imbalance.
Patients and methodsSubjectsNinety-eight cases with NSCLC were enrolled in this
study. Surgeries for radical resection of the tumors were
performed consecutively for each of the patients in the
Department of Thoracic Surgery, Beijing Chest Hospital,
Capital Medical University, between February 2007 and
July 2008. Inclusion criteria consisted of histologically or
cytologically proven NSCLC and all patients were previ-
ously untreated with chemotherapy or radiotherapy. The
pathological surgical staging IaeIIIa was done according
to the 7th edition TNM staging classification in lung cancer.
Simultaneously, 51 healthy volunteers were enrolled as the
control group, brief history and physical examinations
including the routine blood tests, electrocardiogram(ECG), chest X-ray, abdominal and pelvic ultrasound, etc.
confirmed that they were healthy. This study was approved
by the ethic committee of the Beijing Chest Hospital.
Informed consent was obtained from each patient and
healthy control.Serum collection and measurementsFive milliliters of peripheral venous blood was obtained
before surgery, then centrifuged at 1000 g for 15 min in a
refrigerated centrifuge to get serum aliquots and stored at
80 C until further assay. The blood samples from control
subjects were processed similarly. Blood samples were
taken from the female subjects during non-menstrual
period. The concentration of VEGF and endostatin in serum
preoperatively were determined by a quantitative sandwich
enzyme-linked immunosorbent assay (ELISA). The levels
of serum VEGF and endostatin were determined according
to the manufacturer’s instructions of VEGF ELISA kit
(Jingmei Biotech Co., Ltd, Beijing, China) and endostatin
ELISA kit (R&D Systems, Minneapolis, MN, USA). All
determinations were made in duplicate.Statistical analysisStatistical analyses were performed using SPSS 16.0
software (SPSS Inc., Chicago, IL, USA). All data were ex-
pressed as medians, with the 25th percentile and 75th
percentile, due to skewed distribution examined by Kolmo-
goroveSmirnov test. Nonparametric statistical analyses
were performed using ManneWhitney U test determining
the differences between two independent groups and Krus-
kaleWallis test for determining the differences among
more than two groups.
Survival time was defined from the date of surgery to
death or the date of the last follow-up. None of the patients
died within 60 days after operation. Among the 98 patients,
1 patient could not be contacted soon after surgery and 2
patients were lost to follow-up in the third year after the
operation. The median follow-up time was 55.7 months
(range, 3.2e80.1 months).
The impact of the ratio VEGF/endostatin on survival in
the subgroup analysis was assessed with the KaplaneMeier
method and compared by the log rank test. To assess the in-
dependent value of different variables on survival, multivar-
iate analysis was performed using the Cox proportional
hazards model. Variables with p value <0.05 in univariate
analysis were entered into the Cox regression analysis. In
the study, P < 0.05 was considered statistically significant.
ResultsClinicopathological characteristicsThe median age of the patients was 62 years (range,
36e84 years), 82.7% were males. The majority (53.1%)
1138 Y. Hu et al. / EJSO 40 (2014) 1136e1142of tumors were squamous cell carcinoma. Among these 98
patients, pathological tumor stage included 43 (43.9%)
cases at stage I, 22 (22.4%) at stage II, and 33 (33.7%) at
stage III. The most frequently seen histological grade was
moderately differentiated (83.7%) type of the tumor. Of
the total cases, 74 (75.5%) underwent lobectomy, while
20 (20.4%) and 4 (4.1%) received pneumonectomy and
sublobectomy (wedge resection or segmentectomy),
respectively. In the control group, the median age was
60.5 years (range, 55e64 years), 72.5% of them were
male. There were no significant differences in age and
gender between the two groups (Table 1).Circulating VEGF level, endostatin concentration
and the ratio of VEGF/endostatinThe concentration of serum VEGF was significantly
higher in operable NSCLC patients [median, 802.5 pg/mL
(IQR, 501.4e1136.4 pg/mL)] than in healthy controls [me-
dian, 367.3 pg/mL (IQR, 209.9e557.7 pg/mL)]
(P < 0.0001) (Fig. 1A). Similarly, serum level of endostatin
in lung cancer patients [median, 69.0 ng/mL (IQR,
53.3e85.8 ng/mL)] was significantly higher than that of
the control volunteers [median 52.1 ng/mL (IQR,
45.5e83.1 ng/mL)] (P ¼ 0.016) (Fig. 1B). No significant
correlation was found between VEGF and endostatin levels
in both NSCLC patients (r ¼ 0.146, p ¼ 0.151) and controlTable 1
Clinical characteristic of the NSCLC patients.
Characteristics N (%) P
Patients Controls
Total 98 51
Age (years)
Median (min, max) 62 (36e84) 60.5 (55e64) 0.272
Gender
Male 81 (82.7) 37 (72.5) 0.149
Female 17 (17.3) 14 (27.5)
Smoking status
Current or ex-smoker 72 (73.5)
Non-smoker 26 (26.5)
Postsurgical stage
I 43 (43.9)
II 22 (22.4)
IIIA 33 (33.7)
Node invasion
N0 67 (68.4)
N1e2 31 (31.6)
Histology type
Adenocarcinoma 37 (37.8)
Squamous 52 (53.1)
Others 9 (9.2)
Differentiation
Well/moderate 83 (84.7)
Poor 15 (15.3)
Type of resection
Lobectomy/sublobectomy 78 (79.6)
Pneumonectomy 20 (20.4)
NSCLC, non-small lung cancer.cases (r ¼ 0.125, p ¼ 0.383). The ratio of VEGF/endostatin
levels was significantly higher in operable NSCLC patients
[median, 10.4 (IQR, 5.9e19.8)] than in healthy controls
[median, 5.1 (IQR, 3.39e9.75)] (P ¼ 0.002) (Fig. 1C).Clinicopathological characteristics and VEGF/
endostatin levelThe correlation between clinicopathological characteris-
tics and serum level of VEGF, endostatin and the VEGF/en-
dostatin ratio was summarized (Table 2). Circulating VEGF
did not demonstrate any significant relationship with pa-
tients’ clinicopathological features. Serum endostatin was
only significantly higher in patients with poorly differenti-
ated cancer than in those with well or moderately differen-
tiated cancer ( p ¼ 0.014).Survival analysisThe survival analysis of the 95 patients who could be
followed up to the end of the study revealed that 46 of
them (48.4%) were still alive with the median follow-up
time: 74.1 months (range, 62.1e80.1 months). The median
survival time among the patients who died was 16.7 months
(range, 3.2e57.2 months). The survival time of the survi-
vors was significantly longer than that of the non-
survivors ( p < 0.0001).
The serum level of VEGF in the patients still alive was
significantly lower than that in those who died [median,
687.0 pg/mL (IQR, 381.5e932.05 pg/mL) vs. 879.1 pg/
mL (IQR, 529.7e1254.6 pg/mL), respectively]
( p ¼ 0.049) (Fig. 2A). The median level of the VEGF/en-
dostatin ratio of the two groups were 8.3 (IQR, 4.3e17.9)
vs. 12.9 (IQR, 8.0e22.1) respectively, the difference was
also significant ( p ¼ 0.017) (Fig. 2B). The median serum
levels of endostatin were 68.5 ng/mL (IQR,
53.4e97.5 ng/mL) and 69.8 ng/mL (IQR, 52.1e80.5 ng/
mL) respectively, no significant difference was found be-
tween them ( p ¼ 0.396) (Fig. 2C).
The analysis of the impact of VEGF/endostatin ratio on
the survival in the subgroup of patients with pathological
stage N0 showed that, there was a significant increase of
the survival time in the group with lower ratio than in the
group with higher ratio ( p ¼ 0.032) (median, 63.53,
55.67 months, respectively) (Fig. 3).
The prognostic variables were determined by Cox pro-
portional hazard regression analysis. In the univariate anal-
ysis, postsurgical TNM stage ( p < 0.0001), ratio of VEGF/
endostatin ( p ¼ 0.018) and the type of resection
( p ¼ 0.002) were significantly associated with survival
time. The variables with P <0.05 were entered into the
multivariate analysis and the result showed that postsur-
gical stage (P < 0.0001), ratio of VEGF/endostatin
(P ¼ 0.045) and the type of resection (P ¼ 0.001) were
the independent variables correlated with the prognosis of
operable NSCLC (Table 3).
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Figure 1. Circulating level of VEGF, endostatin and VEGF/endostatin ratio between the normal control and the patients with NSCLC. A, B, and C figures
respectively illustrated the level of serum VEGF and endostatin and VEGF/endostatin of patients with NSCLC. The line inside each box represents the me-
dian. The bottom and top limits of each box represents the 5th and 95th percentile, respectively. The black dots represented outliers.
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The aim of this study was to analyze whether there was
an imbalance of the angiogenic inducer and inhibitor inTable 2
Association between clinical characteristics and the level of VEGF, endostatin a
Characteristics Serum VEGF (pg/mL) p Serum
Median (IQR) Median
Overall level 802.50 (501.43e1136.45) 69.00 (
Histology
Adenocarcinoma 760.50 (500.95e1081.75) 0.659 69.50 (
Squamous 836.10 (525.2e1235.08) 71.10 (
others 907.60 (451.90e1495.45) 54.30 (
Differentiation
Poor 861.30 (501.90e1307.30) 0.937 83.50 (
Well/moderate 789.90 (500.00e1123.90) 66.90 (
Lymph node status
N0 861.30 (563.00e1128.40) 0.176 72.10 (
N1e2 621.80 (425.00e1160.60) 65.40 (
Postsurgical stage
I 857.10 (512.60e1078.00) 0.703 68.40 (
II 712.20 (504.20e1490.80) 76.45 (
IIIa 760.50 (436.68e1234.00) 69.50 (
VEGF, vascular endothelial growth factor.
IQR, interquartile range.patients with operable NSCLC, and to study the correlation
between the imbalance and the prognosis.
We hypothesized that there might be an imbalance be-
tween VEGF and endostatin, which represent the importantnd VEGF/E dostatin ratio.
endostatin (ng/mL) p VEGF/endostatin p
(IQR) Median (IQR)
53.35e85.80) 10.40 (5.96e19.82)
56.20e84.25) 0.193 9.56 (6.69e16.53) 0.420
53.25e96.28) 11.18 (5.55e21.19)
47.95e69.30) 20.11 (6.30e33.69)
69.50e98.30) 0.014 8.95 (5.54e14.47) 0.703
22.60 51.40e81.20) 11.67 (6.09e20.11)
53.40e97.20) 0.170 8.95 (5.59e20.04) 0.622
52.70e73.20) 11.86 (7.07e18.81)
51.40e97.20) 0.956 9.93 (5.54e18.79) 0.413
53.20e93.50) 12.31 (6.09e22.99)
54.45e77.63) 10.30 (7.08e18.15)
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Figure 2. Circulating level of VEGF, endostatin and VEGF/endostatin ratio between survivors and non-survivors at 5-year with NSCLC. A, B, and C figures
respectively illustrated the circulating level of serum VEGF and endostatin and VEGF/endostatin of patients with the two groups. The line inside each box
represents the median. The bottom and top limits of each box represents the 5th and 95th percentile, respectively. The black dots represented outliers.
1140 Y. Hu et al. / EJSO 40 (2014) 1136e1142component of the inducers and inhibitors involved in the
angiogenesis. In this study, preoperative serum levels of
VEGF and endostatin were examined and compared to 51
healthy controls by ELISA. The serum levels of VEGF
and endostatin in operable NSCLC patients were signifi-
cantly higher than those in control individuals. The result
was consistent with the reports of other studies.14e17 It is
very interesting that both angiogenic activators and inhibi-
tors are increased. We determined the ratio of VEGF/Figure 3. Association between patients survival and VEGF/endostatin ra-
tio. Overall survival stratified by the V/E ratio level in patients with
N0 (V/E, the ratio of VEGF/endostatin).endostatin and compared it with the ratio of the healthy
control. The ratio was significantly increased in patients
with operable NSCLC. A net balance of angiogenic inhib-
itors over activators would maintain the angiogenic switch
in the off position, whereas a shift to an excess of activating
stimuli would turn on angiogensis.18 So we presumed that
in the process of the angiogenesis, while the positive angio-
genic factors including VEGF were induced to produce
more, the negative angiogenic factors including endostatin
also increased as a feedback to regulate the angiogenesis
balance. But the increase of endostatin may be not propor-
tionate to the increased level of VEGF, the balance would
be changed. Then changes in the balance mediate the
angiogenic switch which would benefit the progress of
the cancer.19
Although it was reported that VEGF was related to en-
dostatin,20 this study did not find significant correlation be-
tween them and it is in accordance with the result that
VEGF and endostatin were not linearly correlated reported
by Suzuki et al.16 Regardless the fact that there is no linear
relationship between the two factors, the ratio of them
might be a valuable variable. The significantly increased
VEGF/endostatin ratio in this study might reflect an imbal-
ance between angiogenic inducer and inhibitor.
Results of studies on prognostic value of VEGF and en-
dostatin were not consistent.21e24 This study did not find
the value of endostatin in the prognostic significance,
although a systematic review with meta-analysis concluded
Table 3
Analysis with overall survival.a
Variables Univariate analysis Multivariate analysis
HR 95%CI p HR 95%CI p
Gender
Male 0.963 0.467e1.985 0.918 Not included in multivariable model
Female
Smoking status
Current or ex-smoke 0.660 0.337e1.291 0.225 Not included in multivariable model
Non-smoker
Postsurgical stage
I 2.312 1.643e3.255 <0.0001 2.245 1.587e3.174 <0.0001
II
IIIA
Histology type
Squamous 1.532 0.931e2.520 0.093 Not included in multivariable model
Adenocarcinoma
Others
Differentiation
Poor 0.656 0.318e1.352 0.253 Not included in multivariable model
Well/moderate
Type of resection
Lobectomy/sublobectomy 2.622 1.405e4.894 0.002 2.938 1.541e5.601 0.001
Pneumonectomy
Serum endostatin (ng/ml) 0.991 0.981e1.002 0.099 Not included in multivariable model
Serum VEGF (pg/ml) 1.000 1.000e1.001 0.070 Not included in multivariable model
VEGF/endostatin ratio 1.029 1.005e1.054 0.018 1.024 1.000e1.048 0.045
HR, hazard ratio; CI, confidence interval; VEGF, vascular endothelial growth factor.
a 97 patients in the analysis. Cox regression analysis.
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NSCLC.25 In the current study lower VEGF level was
found in the patients who lived for more than 5 years
compared with the level of those who lived for less than
5 years. But in univariate analysis, the difference did not
reach the statistical significance. A meta-analysis reported
by Hu et al. demonstrated that high VEGF level was asso-
ciated with poor outcome in inoperable stage instead of in
operable stage.26 As the inconsistent reports about the cor-
relation of VEGF and endostatin with the prognosis, we as-
sume that it might be not enough to assess only the
angiogenic inducers or the inhibitors. In the internal envi-
ronment, the homeostasis is essential for the normal func-
tion and structure.27 So it is necessary to study the
balance of the angiogenic factors.
In the present study, the ratio of VEGF/endostatin was
significantly higher in operable NSCLC cases than in the
normal control. And it correlated with the prognosis of
operable NSCLC. In subgroup analysis, patients with N0
presented significantly different prognosis when the ratio
was divided by the median. To date, although there are lim-
itations and controversies about the TNM staging,28 it still
acts as the best common method for measuring the prog-
nosis to NSCLC. The present study suggests that the
VEGF/endostatin ratio is an independent factor correlated
with the prognosis of NSCLC patients and the ratio might
supplement the limitation of the TNM staging.
To date, two categories of medication are used in the
development of anti-angiogenic therapy, involving theinhibition of angiogenic factors (bevacizumab and ramucir-
umab act through this pathway 29) and the application of
endogenous angiogenesis inhibitors (endostatin is one of
the approved therapy in China 30). Restoration of pro-
and anti-angiogenic balance in tumors may “normalize” tu-
mor vasculature.31 Patients perhaps should be treated with
different types of anti-angiogenic drugs according to the
need of the internal balance of angiogenesis, such as
reducing the angiogenic inducers or increasing the angio-
genic inhibitors, should not be treated with anti-VEGF or
endogenous angiogenic inhibitors without careful
selections.
Conclusions
This investigation revealed that an imbalance between
VEGF and endostatin levels exits in the serum of operable
NSCLC patients. This imbalance predicted the prognosis of
NSCLC patients. However, whether the ratio of VEGF/en-
dostatin can be a predictor for some treatments or progres-
sion/recurrence of the disease should be further explored in
the future. The more we understand the angiogenesis in
NSCLC, the more effective modalities would be applied
to NSCLC patients.
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